Navigating the path forward to conduct clinical research in the midst of the COVID-19 pandemic has introduced unique challenges for sponsors and research institutions alike.

Industry sponsors and institutions are facing unprecedented issues resulting from the COVID-19 outbreak, such as clinical trial site closures, travel restrictions, limitations on the availability of investigational product and threats to the health and well-being of research personnel and study participants.